Tissue Biomarkers in Melanoma Patients Treated with TIL

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Knol, Anne Chantal ^a   Nguyen, Jean Michel ^a,c   Pandolfino, Marie Christine ^a,b   Quéreux, Gaëlle ^a   Brocard, Anabelle ^a   Peuvrel, Lucie ^a   Saint Jean, Mélanie ^a   Saiagh, Soraya ^b   Khammari, Amir ^a   Dréno, Brigitte ^a,b  

^a INSERM   (France)

^b Unité de Thérapie Cellulaire et Génique   (France)

^c CHU DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE; MALE; MELANOMA; OVERALL SURVIVAL; PHENOTYPE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TISSUE INTERACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT;

ADULT; AGED; CELL COUNT; CELL LINE, TUMOR; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 84871425699     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048729     Document Type: Article

References (27)

1. Jotereau F, Labarriere N, Gervois N, Pandolfino MC, Dreno B, (2003) [Passive immunotherapy of melanoma]. Bull Cancer 90: 583-586.
2. Jotereau F, Pandolfino MC, Boudart D, Diez E, Dreno B, et al. (1991) High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10: 405-411.
3. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676-1680.
4. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, et al. (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86: 1159-1166.
5. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
6. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, et al. (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16: 2646-2655.
7. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, et al. (2002) Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 51: 539-546.
8. Khammari A, Nguyen JM, Pandolfino MC, Quereux G, Brocard A, et al. (2007) Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 56: 1853-1860.
9. Pandolfino MC, Labarriere N, Tessier MH, Cassidanius A, Bercegeay S, et al. (2001) High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement. Cancer Immunol Immunother 50: 134-140.
10. Labarriere N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, et al. (2002) Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 51: 532-538.
11. Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, et al. (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62: 5267-5272.
12. Terabe M, Berzofsky JA, (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16: 157-162.
13. Gervois N, Heuze F, Diez E, Jotereau F, (1990) Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol 20: 825-831.
14. Pandolfino MC, Saiagh S, Knol AC, Dreno B, (2010) Comparison of three culture media for the establishment of melanoma cell lines. Cytotechnology 62: 403-412.
15. Jung T, Schauer U, Heusser C, Neumann C, Rieger C, (1993) Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159: 197-207.
16. Chebassier N, El Houssein O, Viegas I, Dreno B, (2004) In vitro induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in keratinocytes by boron and manganese. Exp Dermatol 13: 484-490.
17. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P, (2006) Human T cell responses against melanoma. Annu Rev Immunol 24: 175-208.
18. Garrido F, Cabrera T, Aptsiauri N, (2010) "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127: 249-256.
19. Quereux G, Pandolfino MC, Knol AC, Khammari A, Volteau C, et al. (2007) Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur J Dermatol 17: 295-301.
20. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, et al. (2011) CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 60: 1137-1146.
21. Berd D, (2004) M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 3: 521-527.
22. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, et al. (2011) Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer.
23. Knol AC, Nguyen JM, Quereux G, Brocard A, Khammari A, et al. (2011) Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma. Exp Dermatol 20: 430-434.
24. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, et al. (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9: 204.
25. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, et al. (2009) Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res 15: 390-399.
26. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, et al. (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69: 3077-3085.
27. Gajewski TF, Louahed J, Brichard VG, (2010) Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 16: 399-403.